BEIGENE LTD ⚡️⚡️⚡️ please read
A magical medicine called
BRUKINSA
A CANCER TREATMENT MEDICINE
Hi friends / fellow members ……!
it’s my personal life experience….!
BRUKINSA is the best treatment of choice in my cancer treatment . I am non Hodgkin’s Lymphoma patient and I really thankful to this esteemed company as well as its scientists who invented this medicine to treat the cancer conditions.
I am still alive because of this medicine treatment, so that I would like to support and contribute to this great company. My greatest wish to buy the shares of this company and hold it . Other important reasons are following …
1) Why the stock can still be attractive
Recent fundamental inflection is real. The company’s 2025 annual report news says revenue reached RMB 38.225B , up 40.46% , and it reported its first full-year profit , with net profit of RMB 1.461B . This is the strongest support for the “buy” case because it shows the business is no longer just a cash-burning growth story. 3811
Latest earnings power is positive. Your provided TTM EPS is 2.47 , ROE is 7.46% , and ROA is 3.96% , which is meaningfully better than many late-stage biotech peers that are still loss-making.
Analyst sentiment is constructive. You provided 25 analysts with an average target price of 402.93 , versus a current price of 323.87 . The recommendation mix is also favorable: 7 recommend, 16 buy, 1 hold, 1 underperform . That implies Wall Street is broadly positive, though not unanimously so.
Pipeline/news flow is supportive. Recent news shows a regulator accepted a new indication filing for zanidatamab + tislelizumab in HER2-positive gastroesophageal adenocarcinoma first-line treatment , which is a positive catalyst if it eventually converts into label expansion. 4
2) Why it may not be a clean “buy now”
Valuation is not cheap. The stock trades at P/E 131.12 , P/B 8.81 , and P/S 7.19 . For a company that has only recently turned profitable, these multiples suggest the market is already pricing in a lot of future success.
Forward P/E is still elevated. The latest forward P/E in your data is 54.98 , which is much higher than the historical average shown in the dataset ( 30.22 ). That tells us the market is paying a premium relative to its own recent forward valuation history.
Price is near the upper end of the 52-week range. Current price is 323.87 , with a 52-week high of 385.22 and 52-week low of 218.31 . The stock is much closer to the high than the low, so near-term upside from pure re-rating may be limited unless new catalysts arrive.
Short-term momentum is mixed. Today’s move is positive at +0.99% , but the 5-day capital flow is volatile, with notable outflows on 04-13 (-2505.3K) and a strong inflow on 04-16 (+2772.21K) . That kind of flow pattern usually signals active positioning rather than stable conviction.
Short interest is meaningful. Short volume ratios have often been in the high single digits to mid-teens recently, which suggests some investors still see valuation or execution risk.
3) Technical and market structure view
Current price: 323.87
Today’s high/low: 328.39 / 322.30
Support: 310.47
Resistance: 337.47
Volume ratio: 0.89
This setup suggests the stock is trading above support but below resistance, with no strong breakout confirmation from volume yet. In other words, it is not deeply washed out, but it is also not showing an obvious “buy-the-dip” capitulation setup.
4) My view: who should buy it now?
Reasonable for long-term growth investors: yes, if you want exposure to a biotech company that has moved into profitability and still has pipeline upside.
Less attractive for valuation-sensitive investors: no, because the current multiples already reflect strong expectations.
Best approach: consider waiting for either
a pullback closer to support, or
confirmation that new product/label catalysts are translating into durable earnings growth.
With Loving Regarding
A.John
Hamilton
New Zealand
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
